Ph.D. Supervisor, Researcher, Deputy Director of the Department of Radiation Oncology (acting head), The First Affiliated Hospital of USTC. He specializes in the clinical and research work of radiotherapy for thoracic malignancies. Currently, he is the leader of the Anhui Provincial Clinical Key Specialty (Priority Development). He serves as a Youth Committee Member of the Radiation Oncology Branch of the Chinese Medical Association, a Member and Youth Council Member of the Radiation Oncology Branch of the Chinese Anti-Cancer Association, a Youth Committee Member of the Radiation Oncology Physician Branch of the Chinese Medical Doctor Association, and a Member of the Oncology Branch and Radiation Oncology Branch of the Anhui Medical Association.
Education and Work Experience
- 2003-2008: Bachelor's Degree in Clinical Medicine, Anhui Medical University
- 2008-2013: Ph.D. in Oncology, Sun Yat-sen University
- 2013-2014: Resident Physician, Tianjin Medical University Cancer Institute and Hospital
- 2014-2016: Attending Physician, Tianjin Medical University Cancer Institute and Hospital
- 2017-2019: Associate Chief Physician, Associate Professor, Tianjin Medical University Cancer Institute and Hospital
- 2019-Present: Associate Chief Physician, The First Affiliated Hospital of USTC
- 2019-Present: Special Researcher, University of Science and Technology of China
- 2020-Present: Ph.D. Supervisor, University of Science and Technology of China; Deputy Director (acting head), Department of Radiation Oncology, The First Affiliated Hospital of USTC
Academic Achievements and Impact
Dr. Qian is dedicated to the clinical and research work of radiotherapy for thoracic malignancies. Using esophageal cancer and lung cancer as primary models, his research has delved into new mechanisms of telomerase regulation of DNA damage and cell death, systematically elucidating its role in radiotherapy resistance and exploring therapeutic strategies targeting related pathways. He currently leads three projects funded by the National Natural Science Foundation (two ongoing). As the first author and corresponding author, he has published over 20 SCI papers, including in top journals such as Clinical Cancer Research, International Journal of Radiation Oncology, Biology, Physics, J Pathol, and Nanomed Nanobiotechnol, with a cumulative impact factor exceeding 100. He has been recognized as a second and third-tier innovative talent in Tianjin's 131 Innovative Talent Program and has received the Tianjin Science and Technology Progress First Prize (participant). Two of his studies were presented orally at the American Society for Radiation Oncology (ASTRO) conference. Currently, he is the PI for five single-center and multi-center studies.
Ongoing Projects (Principal Investigator Only)
1. Project Name: Mechanism of PC4 Mediating Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma by Promoting Non-Homologous End Joining Repair of DNA Damage
- Source: National Natural Science Foundation General Project
- Funding: 550,000 RMB
- Duration: 2020-01 to 2023-12
2. Project Name: Mechanism of PinX1/RBM10 Regulating Telomere Stability Mediating Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma Cells
- Source: National Natural Science Foundation
- Funding: 590,000 RMB
- Duration: 2018-01 to 2021-12
3. Project Name: Anhui Provincial Clinical Medicine Key Specialty Project (Priority Development)
- Funding: 1.5 million RMB
- Duration: 2020 to 2024
Main Research Areas (Graduate Programs)
Biology:
1. Radiobiology:
- Research on the regulatory mechanisms of telomeres/telomerase
- Abnormal DNA damage repair and radiotherapy resistance
- Role and mechanism of mitochondria-regulated cell death pathways in radiotherapy resistance of malignant tumors
Clinical Medicine:
1. Radiation Oncology:
- New strategies for early assessment of chemoradiotherapy efficacy in esophageal cancer and establishment of new clinical pathways
- Radiotherapy sensitization strategies targeting telomeres/telomerase
- Synergistic mechanisms and clinical exploration of combined radiotherapy and immunotherapy
- Impact of chemoradiotherapy on tumor immune/vascular microenvironment
Representative Papers (Last Five Years)
1. Peijie Zhou, Wei Liu, Yong Cheng, Dong Qian* (通讯作者). Nanoparticle-based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 May 4;e1718.;
2. Dong Qian#, Yuwen Wang#, Gang Zhao, Fuliang Cao, Puchun Er, Xi Chen, Jingjing Cheng, Wencheng Zhang, Xiaoxia Li, Baozhong Zhang, Yong Guan, Dejun Zhou, Jun Wang, Yunqing Kang, Hongjing Jiang, Zhentao Yu, Zhiyong Yuan, Ping Wang, & Qingsong Pang*. Tumor Remission and tumor-infiltrating lymphocytes during chemoradiotherapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):319-328.;
3. Ding X#, Cheng J#, Pang Q, Wei X, Zhang X, Wang P, Yuan Z*, Qian D* (通讯作者). BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM/CHK1 inhibition. Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):861-874;
4. Cheng J#, Qian D#* (共同第一、共同通讯作者), Ding X#, Song T, Cai M, Dan Xie, Wang Y, Zhao J, Liu Z, Wu Z, Pang Q, Zhu L, Wang P, Hao X*, Yuan Z*. High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients. Cell Death Dis. 2018 Sep 24;9(10):991;
5. Wang Y#, Cheng J#, Xie D, Ding X, Hou H, Chen X, Er P, Zhang F, Zhao L, Yuan Z, Pang Q, Wang P*, Qian D* (通讯作者). NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc. Chinese Journal of Cancer (Cancer Communications).2018 Jun 5;38(1):33;
6. Hou H#, Er P#, Cheng J#, Chen X, Ding X, Wang Y, Chen X, Yuan Z, Pang Q, Wang P*, Qian D* (通讯作者). High expression of FUNDC1 predicts poor prognostic outcomes and is a promising target to improve chemoradiotherapy effects in patients with cervical cancer. Cancer Med. 2017 Aug;6(8):1871-1881;
7. Tian Zhang#, Xiaojie Liu#, Xiuli Chen, Jing Wang, Yuwen Wang, Dong Qian* (共同通讯作者), Qingsong Pang*, Ping Wang*. Inhibition of PC4 radiosensitizes nonsmall cell lung cancer by transcriptionally suppressing XLF. Cancer Med. 2018 Apr;7(4):1326-1337;
8. Dong Qian, Jingjing Cheng, Xiaofeng Ding, Xiuli Chen, Xi Chen, Bin Zhang, Puchun Er, Minghan Qiu, Xianliang Zeng, Yihang Guo, Huanhuan Wang, Lujun Zhao, Dan Xie, Zhiyong Yuan, Ping Wang, Qingsong Pang *. PinX1 suppresses tumorigenesis by negatively regulating telomerase/telomeres in colorectal carcinoma cells and is a promising molecular marker for patient prognosis. OncoTargets and Therapy. 2016:9:4821-4831;
9. 钱东，丁小凤，程菁菁，袁智勇。靶向端粒/端粒酶的抗肿瘤治疗研究进展，中国肿瘤临床. 2016 Vol. 43 (15): 679-682.
10. Puchun Er, Dong Qian（共一）, Wencheng Zhang, Baozhong Zhang, Hui Wei, Tian Zhang, Xi Chen, Yuwen Wang, Jingjing Zhao, Qi Wang, Qingsong Pang, Ping Wang. The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy. Aging-US. 2020 Apr 24;12(8):6586-6599；
11. Qian Dong#, Chen K#, Deng H#, Rao HL, Huang HQ, Liao YJ, Sun X, Lu S, Yuan Z, Xie D*, Cai Q*. MicroRNA-374b suppresses proliferation and promotes apoptosis in T-cell lymphoblastic lymphoma by repressing AKT1 and Wnt-16. Clinical Cancer Research. 2015 Nov 1;21(21):4881-91
Contact Information
E-mail: qiandong@ustc.tsg211.com